Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jorge Cortes

Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval

Clinical Lymphoma, Myeloma and Leukemia

English

Use of Second- And Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm

Clinical Lymphoma, Myeloma and Leukemia

English

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

Clinical Lymphoma, Myeloma and Leukemia

English

Overview, Equivalences and Design Guidelines of V1 Concept: A Voltage Mode Control That Behaves as a Current-Mode With Near Time-Optimal Response

2015

English

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

Journal of Clinical Oncology

English

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Journal of Clinical Oncology

English

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy for Chronic Lymphocytic Leukemia

Journal of Clinical Oncology

English

Result of High-Dose Imatinib Mesylate in Patients With Philadelphia Chromosome--Positive Chronic Myeloid Leukemia After Failure of Interferon-

English

Chromosomal Abnormalities in Philadelphia Chromosome Negative Metaphases Appearing During Imatinib Mesylate Therapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

English

Imatinib Mesylate Therapy May Overcome the Poor Prognostic Significance of Deletions of Derivative Chromosome 9 in Patients With Chronic Myelogenous Leukemia

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jorge Cortes

Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval

Use of Second- And Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

Overview, Equivalences and Design Guidelines of V1 Concept: A Voltage Mode Control That Behaves as a Current-Mode With Near Time-Optimal Response

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy for Chronic Lymphocytic Leukemia

Result of High-Dose Imatinib Mesylate in Patients With Philadelphia Chromosome--Positive Chronic Myeloid Leukemia After Failure of Interferon-

Chromosomal Abnormalities in Philadelphia Chromosome Negative Metaphases Appearing During Imatinib Mesylate Therapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Imatinib Mesylate Therapy May Overcome the Poor Prognostic Significance of Deletions of Derivative Chromosome 9 in Patients With Chronic Myelogenous Leukemia